Atrial Fibrillation Market, by Procedure (Pharmacological (Anti-arrhythmic and Anti-coagulant), Non-Pharmacological (Catheter Ablation Procedures, Maze surgery and Electric Cardioversion), by Technology (Radiofrequency, Laser, Cryotherapy and Others), by End User Hospitals, Speciality, Clinics and Others), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030

Published In : Oct 2022

Code : CMI205

Pages :140

Formats :

Excel and PDF

Industry : Medical Devices

Atrial Fibrillation MarketSize and Trends

Global atrial fibrillation market is estimated to be valued at US$ 21,042.7 million in 2022 and is expected to exhibit a CAGR of 13.4% during the forecast period (2022-2030).

Increasing prevalence of atrial fibrillation is expected to drive the growth of the global atrial fibrillation market over the forecast period.

Increasing prevalence of atrial fibrillation is expected to drive the growth of the global atrial fibrillation market over the forecast period. For instance, according to the data published on July 2022, on Centers for Disease Control and Prevention (CDC), stated that more than 454,000 hospitalizations with atrial fibrillation as the primary diagnosis happen each year in the United States. The condition contributes to about 158,000 deaths each year in U.S.

Increasing approval of products is expected to drive the market growth over the forecast period.

Increasing approval of products is expected to drive the market growth over the forecast period. For instance, in August 2021, Abbott, which is a U.S.-based multinational medical devices and health care company announced that the U.S. Food and Drug Administration (FDA) approved the company's Amplatzer, Left Atrial Appendage Occluder to treat people with atrial fibrillation (AFib) who are at risk of ischemic stroke. The device offers immediate closure of the left atrial appendage (LAA) – an area where blood clots can form in people suffering from AFib – reducing their risk of stroke and immediately eliminating the need for blood-thinning medication.

Global Atrial Fibrillation Market– Impact of Coronavirus (COVID-19) Pandemic

Since the COVID-19 virus outbreak in December 2019, the disease has spread to over 100 countries across the globe and the World Health Organization had declared it a public health emergency on January 30, 2020.

COVID-19 has affected the economy in three main ways: by directly affecting production and demand of drugs and vaccines, by creating disruptions in distribution channels, and through its financial impact on firms and financial markets. Due to nationwide lockdowns, several countries, such as China, India, Saudi Arabia, U.A.E., Egypt, and others, faced problems with regard to the transportation of drugs, medical devices and vaccines from one place to another.

Figure 1. Global Atrial Fibrillation Market Share (%), by End User, 2022